IL6 and systemic lupus erythematosus: F(ab′)2 epratuzumab was able to significantly reduce IL-6 production by anti-BCR alone F(ab′)2 epratuzumab was able to significantly reduce IL-6 production by anti-BCR alone (p<0.01) in HD and SLE cultures, whereas the inhibition by epratuzumab after combined stimulation was not statistically significant.